Efficacy and Safety Study of Symbicort® Turbuhaler® Versus Oxis® Turbuhaler® in Chronic Obstructive Pulmonary Disease (COPD) Patients
Efficacy and Safety Study of Symbicort® Turbuhaler® Versus Oxis® Turbuhaler® in Chronic Obstructive Pulmonary Disease (COPD) Patients
The primary purpose of the study is to investigate if Symbicort is more effective than Oxis
 in increasing forced expiratory volume in one second (FEV1), measured at the clinics, in
 patients with COPD.
Inclusion Criteria:

 -  A current clinical diagnosis of Chronic Obstructive Pulmonary Disease

 -  Documented Chronic Obstructive Pulmonary Disease symptoms for more than 2 years

 -  A smoking history of at least 10 pack years

 Exclusion Criteria:

 -  History and/or current clinical diagnosis of asthma

 -  History and/or current clinical diagnosis of atopic diseases such as allergic rhinitis